Global Vision Biotechnologies was formed in 2012, and since then we’ve invested in the continuous growth of our research and development, our people and our products. We’re committed to improving the quality of life for patients worldwide. This means we also work hand in hand with healthcare providers and industry organizations to support continued research and education programs which provide safe and effective products.

Our facilities located in Vancouver were designed to ensure that our research and development is performed within a strict clinically safe environment. We also ensure that all of our products are manufactured and delivered to patients in their best state. We strive to achieve that medicinal marijuana should be available to every patient that needs it, worldwide.

Global Vision Biotechnologies produces industry-leading research and development which allows for the delivery of superior marijuana-based health care products to patients. Global Vision Biotechnologies leads the industry across diverse disciplines.

Through our strategic partnerships we are now involved with all of the steps necessary to get our clinically approved products to patients. We take a scientific approach to all of our product development and believe that, despite this attention to detail, medicinal marijuana shouldn’t be costly, inconsistent, or difficult to access.

Global Vision Biotechnologies is actively acquiring, or joint venturing, with companies across all sectors of the medical marijuana industry in an effort to build a ‘research-to-sales’ portfolio of complementary companies and joint venture partners. We are committed to providing pharmaceutical-grade medicinal marijuana and superior patient care, while balancing patient economics and returns to shareholders.

Our dedicated team of professionals and partners will always ensure a high-quality product and purity before moving through to production and finally to the point of shipment. Our products are now being sent to dispensaries worldwide, including several dispensaries owned and operated by our partners and shareholders.

Why choose us?

  1. There is a perfect storm on the horizon for the medicinal marijuana industry, as there is a significant economic need for increased patient care in most countries around the world, along with a strong demand for ongoing research and development. Medicinal marijuana is now clinically proven to provide effective medicines, without side effects, for the treatment of chronic pain and conditions.

  2. Dedicated to a patients’ progressive healing, we aim to broaden the understanding of medical marijuana and its therapeutic properties to the medical profession and help meet chronic disease patients’ ongoing needs with customized products. We’re proud to be part of an industry that’s helping patients worldwide to access better medicine; and as we grow, we will continue to provide patients with reliable access to safe, consistent, and effective medicinal marijuana treatments and cures.

  3. One of our main goals is to help build a global medical marijuana brand that’s dependable with therapeutic claims proven and backed up. Through education, research, and development, we will develop and change the cultivation and science of medically authorized marijuana for the better. By developing this new industry by creating a natural product from research-to seed-to sales, we are helping our patients live the life they deserve.

Our Corporate team

Steven Mandson

Chief Executive Officer

Steven Mandson serves as our Chief Executive Officer and has more than 30 years of executive, operational and commercial leadership experience in the bio-pharmaceutical industry, particularly in leading CNS transdermal patch and gel products which has helped CAMM Pharmaceuticals develop their own products adopting similar dispensing methods.

Prior to Global Vision Biotech, Steven served as CEO of two publicly traded companies. Most recently, he was the CEO of a bio-tech company which was acquired by one of the world’s largest pharmaceutical companies during a 5-year tenure.

He assisted with the company acquiring FDA approval of its lead product, which was the first transdermal patch for migraine, to pre-launch before successfully over-seeing the sale of the company. He has also served as the CEO of a NASDAQ listed pharmaceutical company, where under his leadership, sales grew from $42 million to more than $90 million in just 4 years and market capitalization increased from $200 million to more than $500 million.

Steven received a B.S. in Molecular Biology from the University of Toronto - Mississauga, a Ph.D. in Biochemistry from York University, and conducted his postdoctoral training in biophysics and biology at The Canadian Cancer Society Saskatchewan.

Anthony Moreheart

Chief Operating Officer

Anthony Moreheart, M.D. is a board-certified anesthesiologist and is a Diplomate of American Board of Anesthesiology, (DABA). Anthony specializes in pain management and has over 23 years of experience helping thousands of patients manage a multitude of chronically painful medical conditions.

Anthony was one of the original brains associated with the companies origination and is committed to developing further the biotech research in to everything that is clinically related to medicinal marijuana treatments. He has more than 15 years of leadership experience in pharmaceutical research and development and his past roles include leadership positions at two of Canada’s largest pharmaceutical companies.

Anthony has passionately led teams in the discovery and development of a number of first-in-class therapeutic drugs, and has focused his career on developing unique early stage biotechnology to assist with establishing remedies for significant unmet medical conditions. A passion which Anthony has continued with our company.

Matthew Stevens

Chief Financial Officer

Matthew has more than twenty years of senior financial experience with start-up biotechnology, drug delivery and medical device companies. He has been involved with two previous pharmaceutical company IPOs and has raised over $200 million of capital financing.

Matthew has held various leadership positions at several publicly listed pharmaceutical companies, including Senior Vice President, Head Endocrinology and Senior Vice President, Head of Neurology and Immunology.

Matthew was one of the founders of our company and has a passion towards advancing medicinal marijuana for the ultimate benefit and symptom relief of patients worldwide.

Michael Lorthe, Ph.D.

Head of Product Development

Dr. Lorthe is our Head of Product Development and is responsible for the day-to-day management of our research and development activities as well as supporting the commercialization of the company’s products.

Dr. Lorthe has over two decades of pharmaceutical development experience with an emphasis on project management, pharmacology and toxicology.

Dr. Lorthe also has more than 30 years of executive, development and operational experience in the bio-pharmaceutical industry, particularly in CNS product development including epilepsy, pain, depression and schizophrenia. He has been responsible for more than 10 regulatory submissions and approvals of new pharmaceutical products, including transdermal patch and gel products.

Dr. Lorthe has a broad range of development experience, starting from early drug discovery and clinical trials through to regulatory approval and commercial launch. He completed his Ph.D. at the University of Alberta Faculty of Science.

Michelle Smithwell, Ph.D.

Director of Formulation Sciences

Dr. Michelle Smithwell, Ph.D., has more than 15 years of experience developing formulations of pharmaceuticals, biologicals, and vaccines for alternative routes of delivery, including sublingual, nasal, transdermal, and inhalation

Previously, Dr. Smithwell successfully led the effort to develop, achieve regulatory approval, and complete manufacturing of the first tincture and transdermal patch used in the treatment of severe pain relief.

Dr. Smithwell also led the formulation and spray-drying process development of the first inhaled dry powder measles vaccine to successfully complete a Phase 1 clinical trial. She has a broad experience in early-stage R&D, formulation and process development, and technology transfer for GMP manufacturing.

Dr. Smithwell graduated with a Ph.D. in Biochemistry and Genetics from York University, Toronto and conducted post-doctoral research at the Wilfrid Laurier University, Waterloo, Canada.

Matthew Prundle, Pharm D

Director of Medical Services

Matthew Prundle, Pharm D, has served as our Director of Medical Services since July 2011. Matthew is a senior pharmaceutical executive with more than 30 years of experience in clinical development, medical affairs and commercialization in CNS therapy areas.

During his career, he has led numerous successful clinical development programs, regulatory approvals and product launches. Prior to joining Global Vision Biotech, he served as head of Medical Affairs for a large NYSE listed medical research company.

There he was instrumental in the clinical development of their international medical affairs’ teams in neurology and psychiatry. Additionally, he led several successful commercial product launches for some of the more accepted medicines currently being used by psychiatrists worldwide. He earned his Doctor of Pharmacy degree at the University of British Columbia and his MBA at the Trinity Western University.

He has several published articles relating to the use of medical marijuana and the differing experiences between men and women who use medicinal marijuana for Parkinson’s disease tremor and has recently completed a clinical report on the findings.

Matthew also serves on the Board of Visitors at The School of Pharmacy at the University of Waterloo and as a board member of several non-profit medical organizations.

Rob Jeffreys

Investor Relations Officer

Rob Jeffreys serves as Global Vision Biotech’s Investor Relations Officer. Mr. Jeffreys is a seasoned executive who has held management, financial and strategic planning roles in his 28-year tenure in the pharmaceutical industry.

Prior to Global Vision Biotech, he was Senior Vice President, Chief Financial Officer, at one of the world’s most well-respected pharmaceutical giants and focused on their self-administered parenteral product range. He has also held the role of Chief Financial Officer with Auxilium Pharmaceuticals, as well as additional general management, business development and strategic planning responsibilities with them.

Mr. Jeffreys has over two decades of experience working with emerging growth companies and the investors that support them, including eight years as Vice President with a Canadian bio-tech company that he helped take public and sell for nearly $200 million.

Mr. Jeffreys holds a BS from the University of Manitoba and sits on several committees that explore the clinical benefits of medicinal marijuana for children.

James Rollins, PhD

Director of Cannabinoid Research

Dr. James Rollins, PhD, serves as our Director of Cannabinoid Research. Dr. Rollins is also an Adjunct Assistant Professor in the Department of Psychiatry at the McGill University, Montreal.

Prior to joining Global Vision Biotech, he was a Research Health Science Specialist at the Canadian Centre on Substance Use and Addiction in Ottawa as well as sitting on the board at the National Center for Post-traumatic Stress Disorder, (PTSD), at The Life Line Canada Foundation. He is also the former Executive Director at the Institute for Research on Cannabinoids, (IROC), in Colorado Springs, Colorado.

As an early research pioneer of marijuana comorbidity, Dr. Rollins has spent over a decade investigating the interrelations between marijuana and a number of health conditions, including chronic pain, HIV, PTSD, and sleep disorders for the purposes of treatment development and refinement. His research has spanned from laboratory-controlled to clinical trials and pre-implementation. Dr. Rollins has published well over 100 peer-reviewed empirical publications, and he serves on the editorial boards of six scientific journals.

Dr. Rollins earned a BA in psychology and PhD in clinical psychology from the University of Toronto and has also completed a pre-doctoral clinical psychology internship at the Memorial University of Newfoundland and a joint postdoctoral fellowship at the Calgary Clinical Psychology institute.


Information is shared openly and clearly to allow for greater care to patient needs.


Our interaction with our partners, patients and shareholders are always respectful, honest, and forthright.


Our sense of passion in completing our work ensures the importance of delivering ground-breaking research when it’s needed.


Challenges, however difficult they may be, only strengthens our perseverance and persistence.

Mission and Vision

With an ethical integrity and a commitment to our patients in mind, we research, develop and produce clinically proven medicinal marijuana medication.


Dedicated Research - Clinically Proven Cures - Unquestionable Ethics.